S-ClassAbout S-Class
S
SMMTAI Stock Diagnostic Report
Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trial
Summit Therapeutics' key therapeutic agent has demonstrated superior efficacy compared to AstraZeneca's drug in late-stage clinical trials, leading to an increase in its stock price.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$13.359999656677246Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support12.07
Near-Term Resistance15.75
02
FUNDAMENTALS
Financial & Fundamental Analysis
The increase in pipeline value expected from clinical success is promising; however, specific changes in financial metrics or contributions to performance depend on the progress of additional pipeline developments, necessitating a cautious approach.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $13.36 is positioned in the middle range between the 20-day low support level ($12.07) and the high resistance level ($15.75). Since the moving averages are not yet aligned, a split approach near the support line is valid.
Support12.07
Resistance15.75
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The new drug candidate ivonescimab, licensed from Akeso, has demonstrated excellent results in late-stage clinical trials against AstraZeneca's Imfinzi, garnering market attention.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-26)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.